bioAffinity Technologies (BIAF) vs. The Competition Critical Review

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare bioAffinity Technologies to similar businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Profitability

This table compares bioAffinity Technologies and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.68%	-18.55%	-11.34%

Earnings and Valuation

This table compares bioAffinity Technologies and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-3.07
bioAffinity Technologies Competitors	$1.55 billion	$101.44 million	-0.38

bioAffinity Technologies’ peers have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ peers have a beta of 6.02, indicating that their average share price is 502% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for bioAffinity Technologies and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	814	1297	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 9.01%. Given bioAffinity Technologies’ peers higher probable upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its peers.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by insiders. Comparatively, 16.9% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

bioAffinity Technologies peers beat bioAffinity Technologies on 9 of the 10 factors compared.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.